Context Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Context Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-47,200	Closed	-$3K	–	452
2022 Q4	$3K	Hold	47,200	–	–	﹤0.01%	402
2022 Q3	$3K	Hold	47,200	–	–	﹤0.01%	543
2022 Q2	$4K	Sell	47,200 -50,000	-51%	-$10.3K	﹤0.01%	578
2022 Q1	$23K	Hold	97,200	–	–	﹤0.01%	571
2021 Q4	$64K	Buy	+97,200	New	+$67.4K	0.01%	456

Context Capital Management's BIOTW Position: Q1 2023 in Review

Context Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 47,200 shares — an estimated $3K sold.

Context Capital Management first reported a position in BIOTW in Q4 2021 and held it in 5 quarters. The position peaked at $64K in Q4 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Context Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Context Capital Management sold 47,200 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $3K.
Context Capital Management first reported a position in Biotech Acquisition Company Warrant in Q4 2021 and held it in 5 quarters.
Context Capital Management's Biotech Acquisition Company Warrant position peaked at $64K in Q4 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Context Capital Management's 13F filing for Q1 2023, filed 8 May 2023.